RhumbLine Advisers’s Terns Pharmaceuticals TERN Stock Holding History

RhumbLine Advisers’s Portfolio TERN Stock Details TERN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-123,334	Closed	-$6.5M	–	4250
2026 Q1	$6.5M	Buy	123,334 +17,093	+16%	+$702K	0.01%	1269
2025 Q4	$4.29M	Buy	106,241 +1,404	+1%	+$32.4K	﹤0.01%	1471
2025 Q3	$787K	Sell	104,837 -1,614	-2%	-$10.3K	﹤0.01%	2389
2025 Q2	$397K	Buy	106,451 +9,792	+10%	+$30.6K	﹤0.01%	2827
2025 Q1	$267K	Sell	96,659 -1,233	-1%	-$5.04K	﹤0.01%	2955
2024 Q4	$542K	Buy	97,892 +13,479	+16%	+$91.3K	﹤0.01%	2636
2024 Q3	$704K	Sell	84,413 -4,228	-5%	-$34.8K	﹤0.01%	2474
2024 Q2	$604K	Buy	88,641 +29,659	+50%	+$180K	﹤0.01%	2539
2024 Q1	$387K	Buy	58,982 +1,419	+2%	+$9.27K	﹤0.01%	2816
2023 Q4	$374K	Sell	57,563 -1,566	-3%	-$8.28K	﹤0.01%	2832
2023 Q3	$297K	Buy	59,129 +1,179	+2%	+$7.48K	﹤0.01%	2941
2023 Q2	$507K	Buy	+57,950	New	+$675K	﹤0.01%	2675

Other funds holding TERN

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

RhumbLine Advisers's TERN Position: Q2 2026 in Review

RhumbLine Advisers sold out of Terns Pharmaceuticals (TERN) in Q2 2026, closing a stake of 123,334 shares — an estimated $6.5M sold.

RhumbLine Advisers first reported a position in TERN in Q2 2023 and held it in 12 quarters. The position peaked at $6.5M in Q1 2026. 1 fund tracked by Wall St. Rank holds TERN as of Q2 2026.

RhumbLine Advisers reported no remaining Terns Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
RhumbLine Advisers sold 123,334 Terns Pharmaceuticals shares in Q2 2026, an estimated $6.5M.
RhumbLine Advisers first reported a position in Terns Pharmaceuticals in Q2 2023 and held it in 12 quarters.
RhumbLine Advisers's Terns Pharmaceuticals position peaked at $6.5M in Q1 2026.
1 fund tracked by Wall St. Rank held Terns Pharmaceuticals as of Q2 2026.

Based on RhumbLine Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.